Cargando…
Primary Pulmonary Malignant Melanoma Successfully Treated with Immunotherapy in a 90-Year-Old Patient
Malignant melanoma is a rare and high-grade cancer. It most commonly affects the skin, but it has the potential to involve all areas of the body. Primary pulmonary malignant melanoma is rare, accounting for only 0.01% of all pulmonary tumors. We present a case of primary pulmonary malignant melanoma...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149516/ https://www.ncbi.nlm.nih.gov/pubmed/35702556 http://dx.doi.org/10.1159/000524197 |
_version_ | 1784717219455827968 |
---|---|
author | Fujita, Kohei Nakatani, Koichi Imakita, Takuma Kanai, Osamu Mio, Tadashi |
author_facet | Fujita, Kohei Nakatani, Koichi Imakita, Takuma Kanai, Osamu Mio, Tadashi |
author_sort | Fujita, Kohei |
collection | PubMed |
description | Malignant melanoma is a rare and high-grade cancer. It most commonly affects the skin, but it has the potential to involve all areas of the body. Primary pulmonary malignant melanoma is rare, accounting for only 0.01% of all pulmonary tumors. We present a case of primary pulmonary malignant melanoma in a 90-year-old patient. The pretreatment computed tomography (CT) showed a pulmonary mass in the right upper lobe, multiple pleural nodules, enlarged mediastinal lymph nodes, and bone metastases. Positron emission tomography-CT showed a region of fluorodeoxyglucose hyperaccumulation that was consistent with the abnormal shadows. Advanced stage lung cancer was initially suspected, but bronchoscopy revealed a malignant melanoma. The patient was diagnosed with a primary pulmonary malignant melanoma. Although the patient was older, he wanted to receive immediate treatment. Thus, he was treated with immune checkpoint inhibitors. He responded well to the medication, and neither major adverse events nor tumor size reduction was observed. We report a rare case of primary pulmonary malignant melanoma in an older adult. Immune checkpoint inhibitor therapy, as in this case, was a viable treatment option for older adults. |
format | Online Article Text |
id | pubmed-9149516 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | S. Karger AG |
record_format | MEDLINE/PubMed |
spelling | pubmed-91495162022-06-13 Primary Pulmonary Malignant Melanoma Successfully Treated with Immunotherapy in a 90-Year-Old Patient Fujita, Kohei Nakatani, Koichi Imakita, Takuma Kanai, Osamu Mio, Tadashi Case Rep Oncol Case Report Malignant melanoma is a rare and high-grade cancer. It most commonly affects the skin, but it has the potential to involve all areas of the body. Primary pulmonary malignant melanoma is rare, accounting for only 0.01% of all pulmonary tumors. We present a case of primary pulmonary malignant melanoma in a 90-year-old patient. The pretreatment computed tomography (CT) showed a pulmonary mass in the right upper lobe, multiple pleural nodules, enlarged mediastinal lymph nodes, and bone metastases. Positron emission tomography-CT showed a region of fluorodeoxyglucose hyperaccumulation that was consistent with the abnormal shadows. Advanced stage lung cancer was initially suspected, but bronchoscopy revealed a malignant melanoma. The patient was diagnosed with a primary pulmonary malignant melanoma. Although the patient was older, he wanted to receive immediate treatment. Thus, he was treated with immune checkpoint inhibitors. He responded well to the medication, and neither major adverse events nor tumor size reduction was observed. We report a rare case of primary pulmonary malignant melanoma in an older adult. Immune checkpoint inhibitor therapy, as in this case, was a viable treatment option for older adults. S. Karger AG 2022-04-13 /pmc/articles/PMC9149516/ /pubmed/35702556 http://dx.doi.org/10.1159/000524197 Text en Copyright © 2022 by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
spellingShingle | Case Report Fujita, Kohei Nakatani, Koichi Imakita, Takuma Kanai, Osamu Mio, Tadashi Primary Pulmonary Malignant Melanoma Successfully Treated with Immunotherapy in a 90-Year-Old Patient |
title | Primary Pulmonary Malignant Melanoma Successfully Treated with Immunotherapy in a 90-Year-Old Patient |
title_full | Primary Pulmonary Malignant Melanoma Successfully Treated with Immunotherapy in a 90-Year-Old Patient |
title_fullStr | Primary Pulmonary Malignant Melanoma Successfully Treated with Immunotherapy in a 90-Year-Old Patient |
title_full_unstemmed | Primary Pulmonary Malignant Melanoma Successfully Treated with Immunotherapy in a 90-Year-Old Patient |
title_short | Primary Pulmonary Malignant Melanoma Successfully Treated with Immunotherapy in a 90-Year-Old Patient |
title_sort | primary pulmonary malignant melanoma successfully treated with immunotherapy in a 90-year-old patient |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9149516/ https://www.ncbi.nlm.nih.gov/pubmed/35702556 http://dx.doi.org/10.1159/000524197 |
work_keys_str_mv | AT fujitakohei primarypulmonarymalignantmelanomasuccessfullytreatedwithimmunotherapyina90yearoldpatient AT nakatanikoichi primarypulmonarymalignantmelanomasuccessfullytreatedwithimmunotherapyina90yearoldpatient AT imakitatakuma primarypulmonarymalignantmelanomasuccessfullytreatedwithimmunotherapyina90yearoldpatient AT kanaiosamu primarypulmonarymalignantmelanomasuccessfullytreatedwithimmunotherapyina90yearoldpatient AT miotadashi primarypulmonarymalignantmelanomasuccessfullytreatedwithimmunotherapyina90yearoldpatient |